<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="interaction" /><meta name="keywords" content="" /><title>Anti-arrhythmics: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="bnf_int116-anti-arrhythmics.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="bnf_int116-anti-arrhythmics.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=bnf_int116-anti-arrhythmics.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP8848-interactions.htm">Appendix 1 Interactions</a> &gt; <a href="PHP8852-list-of-drug-interactions.htm">List of drug interactions</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="bnf_int115-sodium-bicarbonate.htm" title="Previous: Sodium Bicarbonate">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="bnf_int1176-dronedarone.htm" title="Next: Dronedarone">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1>Anti-arrhythmics</h1><?highlighter on?><div id="pC" class="jN"><p><strong>Anti-arrhythmics</strong> has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int116-anti-arrhythmics.htm">Anti-arrhythmics</a></td><td class="cAI"><p><span>increased myocardial depression when </span> <span>anti-arrhythmics</span> <span>given with other</span> <span>anti-arrhythmics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int363-antipsychotics.htm">Antipsychotics</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>anti-arrhythmics</span> <span>that prolong the QT interval given with</span> <span>antipsychotics</span> <span>that prolong the QT interval</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with myelosuppressive drugs</p></div></td></tr><tr><td><a href="bnf_int440-beta-blockers.htm">Beta-blockers</a></td><td class="cAI"><p><span>increased myocardial depression when </span> <span>anti-arrhythmics</span> <span>given with</span> <span>beta-blockers</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</p></div></td></tr><tr><td><a href="bnf_int54-bupivacaine.htm">Bupivacaine</a></td><td><p><span>increased myocardial depression when </span> <span>anti-arrhythmics</span> <span>given with</span> <span>bupivacaine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int906-levobupivacaine.htm">Levobupivacaine</a></td><td><p><span>increased myocardial depression when </span> <span>anti-arrhythmics</span> <span>given with</span> <span>levobupivacaine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int873-prilocaine.htm">Prilocaine</a></td><td><p><span>increased myocardial depression when </span> <span>anti-arrhythmics</span> <span>given with</span> <span>prilocaine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int888-ropivacaine.htm">Ropivacaine</a></td><td><p><span>increased myocardial depression when </span> <span>anti-arrhythmics</span> <span>given with</span> <span>ropivacaine</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Dronedarone</strong> belongs to <strong>Anti-arrhythmics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>dronedarone</span> <span>given with</span> <span>amiodarone</span> <span>—avoid concomitant use</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int241-antidepressants-tricyclic.htm">Antidepressants, Tricyclic</a></td><td class="cAI"><p><span>manufacturer of </span> <span>dronedarone</span> <span>advises avoid concomitant use with</span> <span>tricyclics</span> <span>(risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int601-atorvastatin.htm">Atorvastatin</a></td><td><p><span></span> <span>dronedarone</span> <span>possibly increases plasma concentration of</span> <span>atorvastatin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>dronedarone</span> <span>possibly reduced by</span> <span>carbamazepine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td class="cAI"><p><span>manufacturer of </span> <span>dronedarone</span> <span>advises avoid concomitant use with</span> <span>clarithromycin</span> <span>(risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>dronedarone</span> <span>possibly enhances anticoagulant effect of</span> <span>coumarins</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int1120-dabigatran-etexilate.htm">Dabigatran Etexilate</a></td><td class="cAI"><p><span></span> <span>dronedarone</span> <span>increases plasma concentration of</span> <span>dabigatran etexilate</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td class="cAI"><p><span></span> <span>dronedarone</span> <span>increases plasma concentration of</span> <span>digoxin</span> <span>(halve dose of <span>digoxin</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int468-diltiazem.htm">Diltiazem</a></td><td class="cAI"><p><span>increased risk of bradycardia and myocardial depression when </span> <span>dronedarone</span> <span>given with</span> <span>diltiazem</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int119-disopyramide.htm">Disopyramide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>dronedarone</span> <span>given with</span> <span>disopyramide</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>dronedarone</span> <span>increased by</span> <span>erythromycin</span> <span>(increased risk of ventricular arrhythmias—avoid concomitant use)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int1226-fidaxomicin.htm">Fidaxomicin</a></td><td><p><span>avoidance of </span> <span>dronedarone</span> <span>advised by manufacturer of</span> <span>fidaxomicin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1202-fingolimod.htm">Fingolimod</a></td><td class="cAI"><p><span>possible increased risk of bradycardia when </span> <span>dronedarone</span> <span>given with</span> <span>fingolimod</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int829-grapefruit-juice.htm">Grapefruit Juice</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>dronedarone</span> <span>increased by</span> <span>grapefruit juice</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td class="cAI"><p><span>manufacturer of </span> <span>dronedarone</span> <span>advises avoid concomitant use with</span> <span>itraconazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>dronedarone</span> <span>increased by</span> <span>ketoconazole</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int451-metoprolol.htm">Metoprolol</a></td><td><p><span></span> <span>dronedarone</span> <span>possibly increases plasma concentration of</span> <span>metoprolol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int475-nifedipine.htm">Nifedipine</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>dronedarone</span> <span>increased by</span> <span>nifedipine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int223-phenindione.htm">Phenindione</a></td><td class="cAI"><p><span></span> <span>dronedarone</span> <span>possibly enhances anticoagulant effect of</span> <span>phenindione</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control  </p></div></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>dronedarone</span> <span>possibly reduced by</span> <span>phenobarbital</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int373-phenothiazines.htm">Phenothiazines</a></td><td class="cAI"><p><span>manufacturer of </span> <span>dronedarone</span> <span>advises avoid concomitant use with</span> <span>phenothiazines</span> <span>(risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>dronedarone</span> <span>possibly reduced by</span> <span>phenytoin</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1060-posaconazole.htm">Posaconazole</a></td><td class="cAI"><p><span>manufacturer of </span> <span>dronedarone</span> <span>advises avoid concomitant use with</span> <span>posaconazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int793-propranolol.htm">Propranolol</a></td><td><p><span></span> <span>dronedarone</span> <span>possibly increases plasma concentration of</span> <span>propranolol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>dronedarone</span> <span>reduced by</span> <span>rifampicin</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>manufacturer of </span> <span>dronedarone</span> <span>advises avoid concomitant use with</span> <span>ritonavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int974-rosuvastatin.htm">Rosuvastatin</a></td><td><p><span></span> <span>dronedarone</span> <span>possibly increases plasma concentration of</span> <span>rosuvastatin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>dronedarone</span> <span>given with</span> <span>saquinavir</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span> <span>dronedarone</span> <span>given with</span> <span>simvastatin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int921-sirolimus.htm">Sirolimus</a></td><td><p><span>manufacturer of </span> <span>dronedarone</span> <span>advises caution with</span> <span>sirolimus</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int455-sotalol.htm">Sotalol</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>dronedarone</span> <span>given with</span> <span>sotalol</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>dronedarone</span> <span>possibly reduced by</span> <span>St John's wort</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td><p><span>manufacturer of </span> <span>dronedarone</span> <span>advises caution with</span> <span>tacrolimus</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td class="cAI"><p><span>manufacturer of </span> <span>dronedarone</span> <span>advises avoid concomitant use with</span> <span>telithromycin</span> <span>(risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int467-verapamil.htm">Verapamil</a></td><td class="cAI"><p><span>increased risk of bradycardia and myocardial depression when </span> <span>dronedarone</span> <span>given with</span> <span>verapamil</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td class="cAI"><p><span>manufacturer of </span> <span>dronedarone</span> <span>advises avoid concomitant use with</span> <span>voriconazole</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Adenosine</strong> belongs to <strong>Anti-arrhythmics</strong> and has the following interaction information:</p><div class="cG"><p><strong>Note:</strong> Possibility of interaction with drugs tending to impair myocardial conduction</p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int362-dipyridamole.htm">Dipyridamole</a></td><td class="cAI"><p><span>effect of </span> <span>adenosine</span> <span>enhanced and extended by</span> <span>dipyridamole</span> <span>(important risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1082-nicotine.htm">Nicotine</a></td><td><p><span>effects of </span> <span>adenosine</span> <span>possibly enhanced by</span> <span>nicotine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int734-theophylline.htm">Theophylline</a></td><td><p><span>anti-arrhythmic effect of </span> <span>adenosine</span> <span>antagonised by</span> <span>theophylline</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Amiodarone</strong> belongs to <strong>Anti-arrhythmics</strong> and has the following interaction information:</p><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int551-acetazolamide.htm">Acetazolamide</a></td><td><p><span>increased cardiac toxicity with </span> <span>amiodarone</span> <span>if hypokalaemia occurs with</span> <span>acetazolamide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1012-agalsidase-alfa-and-beta.htm">Agalsidase Alfa and Beta</a></td><td><p><span></span> <span>amiodarone</span> <span>possibly inhibits effects of</span> <span>agalsidase alfa and beta</span> <span>(manufacturers of <span>agalsidase alfa and beta</span> advise avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int809-amisulpride.htm">Amisulpride</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>amiodarone</span> <span>given with</span> <span>amisulpride</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int241-antidepressants-tricyclic.htm">Antidepressants, Tricyclic</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>amiodarone</span> <span>given with</span> <span>tricyclics</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1168-arsenic-trioxide.htm">Arsenic Trioxide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>amiodarone</span> <span>given with</span> <span>arsenic trioxide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int937-artemether-with-lumefantrine.htm">Artemether with Lumefantrine</a></td><td class="cAI"><p><span>avoidance of </span> <span>amiodarone</span> <span>advised by manufacturer of</span> <span>artemether/lumefantrine</span> <span>(risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>amiodarone</span> <span>possibly increased by</span> <span>atazanavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1009-atomoxetine.htm">Atomoxetine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>amiodarone</span> <span>given with</span> <span>atomoxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int385-benperidol.htm">Benperidol</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>amiodarone</span> <span>given with</span> <span>benperidol</span> <span>—manufacturer of <span>benperidol</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int440-beta-blockers.htm">Beta-blockers</a></td><td class="cAI"><p><span>increased risk of bradycardia, AV block and myocardial depression when </span> <span>amiodarone</span> <span>given with</span> <span>beta-blockers</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</p></div></td></tr><tr><td><a href="bnf_int335-chloroquine-and-hydroxychloroquine.htm">Chloroquine and Hydroxychloroquine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>amiodarone</span> <span>given with</span> <span>chloroquine and hydroxychloroquine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td><p><span></span> <span>amiodarone</span> <span>possibly increases plasma concentration of</span> <span>ciclosporin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>plasma concentration of </span> <span>amiodarone</span> <span>increased by</span> <span>cimetidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int483-colchicine.htm">Colchicine</a></td><td class="cAI"><p><span></span> <span>amiodarone</span> <span>possibly increases risk of</span> <span>colchicine</span> <span>toxicity</span>  </p></td><td></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>amiodarone</span> <span>inhibits metabolism of</span> <span>coumarins</span> <span>(enhanced anticoagulant effect)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int1120-dabigatran-etexilate.htm">Dabigatran Etexilate</a></td><td class="cAI"><p><span></span> <span>amiodarone</span> <span>increases plasma concentration of</span> <span>dabigatran etexilate</span> <span>(reduce dose of <span>dabigatran etexilate</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td class="cAI"><p><span></span> <span>amiodarone</span> <span>increases plasma concentration of</span> <span>digoxin</span> <span>(halve dose of <span>digoxin</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int468-diltiazem.htm">Diltiazem</a></td><td class="cAI"><p><span>increased risk of bradycardia, AV block and myocardial depression when </span> <span>amiodarone</span> <span>given with</span> <span>diltiazem</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int119-disopyramide.htm">Disopyramide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>amiodarone</span> <span>given with</span> <span>disopyramide</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int539-diuretics-loop.htm">Diuretics, Loop</a></td><td><p><span>increased cardiac toxicity with </span> <span>amiodarone</span> <span>if hypokalaemia occurs with</span> <span>loop diuretics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int525-diuretics-thiazide-and-related.htm">Diuretics, Thiazide and related</a></td><td><p><span>increased cardiac toxicity with </span> <span>amiodarone</span> <span>if hypokalaemia occurs with</span> <span>thiazides and related diuretics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1176-dronedarone.htm">Dronedarone</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>amiodarone</span> <span>given with</span> <span>dronedarone</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1152-droperidol.htm">Droperidol</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>amiodarone</span> <span>given with</span> <span>droperidol</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1025-eplerenone.htm">Eplerenone</a></td><td><p><span></span> <span>amiodarone</span> <span>increases plasma concentration of</span> <span>eplerenone</span> <span>(reduce dose of <span>eplerenone</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>amiodarone</span> <span>given with parenteral</span> <span>erythromycin</span> <span>—avoid concomitant use</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int1226-fidaxomicin.htm">Fidaxomicin</a></td><td><p><span>avoidance of </span> <span>amiodarone</span> <span>advised by manufacturer of</span> <span>fidaxomicin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1202-fingolimod.htm">Fingolimod</a></td><td class="cAI"><p><span>possible increased risk of bradycardia when </span> <span>amiodarone</span> <span>given with</span> <span>fingolimod</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int120-flecainide.htm">Flecainide</a></td><td class="cAI"><p><span></span> <span>amiodarone</span> <span>increases plasma concentration of</span> <span>flecainide</span> <span>(halve dose of <span>flecainide</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1019-fosamprenavir.htm">Fosamprenavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>amiodarone</span> <span>possibly increased by</span> <span>fosamprenavir</span> <span>(increased risk of ventricular arrhythmias—avoid concomitant use)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Fosamprenavir is a prodrug of amprenavir</p></div></td></tr><tr><td><a href="bnf_int829-grapefruit-juice.htm">Grapefruit Juice</a></td><td><p><span>plasma concentration of </span> <span>amiodarone</span> <span>increased by</span> <span>grapefruit juice</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int387-haloperidol.htm">Haloperidol</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>amiodarone</span> <span>given with</span> <span>haloperidol</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>amiodarone</span> <span>possibly increased by</span> <span>indinavir</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1050-ivabradine.htm">Ivabradine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>amiodarone</span> <span>given with</span> <span>ivabradine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int840-levofloxacin.htm">Levofloxacin</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>amiodarone</span> <span>given with</span> <span>levofloxacin</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int372-lithium.htm">Lithium</a></td><td class="cAI"><p><span>manufacturer of </span> <span>amiodarone</span> <span>advises avoid concomitant use with</span> <span>lithium</span> <span>(risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int337-mefloquine.htm">Mefloquine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>amiodarone</span> <span>given with</span> <span>mefloquine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int841-mizolastine.htm">Mizolastine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>amiodarone</span> <span>given with</span> <span>mizolastine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int973-moxifloxacin.htm">Moxifloxacin</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>amiodarone</span> <span>given with</span> <span>moxifloxacin</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int842-nelfinavir.htm">Nelfinavir</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>amiodarone</span> <span>given with</span> <span>nelfinavir</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int856-orlistat.htm">Orlistat</a></td><td><p><span>plasma concentration of </span> <span>amiodarone</span> <span>possibly reduced by</span> <span>orlistat</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int808-pentamidine-isetionate.htm">Pentamidine Isetionate</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>amiodarone</span> <span>given with</span> <span>pentamidine isetionate</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int223-phenindione.htm">Phenindione</a></td><td class="cAI"><p><span></span> <span>amiodarone</span> <span>inhibits metabolism of</span> <span>phenindione</span> <span>(enhanced anticoagulant effect)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control  </p></div></td></tr><tr><td><a href="bnf_int373-phenothiazines.htm">Phenothiazines</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>amiodarone</span> <span>given with</span> <span>phenothiazines</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span></span> <span>amiodarone</span> <span>inhibits metabolism of</span> <span>phenytoin</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int369-pimozide.htm">Pimozide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>amiodarone</span> <span>given with</span> <span>pimozide</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int341-quinine.htm">Quinine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>amiodarone</span> <span>given with</span> <span>quinine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>amiodarone</span> <span>increased by</span> <span>ritonavir</span> <span>(increased risk of ventricular arrhythmias—avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>amiodarone</span> <span>given with</span> <span>saquinavir</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span> <span>amiodarone</span> <span>given with</span> <span>simvastatin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int455-sotalol.htm">Sotalol</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>amiodarone</span> <span>given with</span> <span>sotalol</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int208-sulfamethoxazole.htm">Sulfamethoxazole</a></td><td><p><span>possible increased risk of ventricular arrhythmias when </span> <span>amiodarone</span> <span>given with</span> <span>sulfamethoxazole</span> <span>(as co-trimoxazole)—manufacturer of <span>amiodarone</span> advises avoid concomitant use of co-trimoxazole</span>  </p></td><td></td></tr><tr><td><a href="bnf_int371-sulpiride.htm">Sulpiride</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>amiodarone</span> <span>given with</span> <span>sulpiride</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td class="cAI"><p><span>avoidance of </span> <span>amiodarone</span> <span>advised by manufacturer of</span> <span>telaprevir</span> <span>(risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int935-thyroid-hormones.htm">Thyroid Hormones</a></td><td><p><span>for concomitant use of </span> <span>amiodarone</span> <span>and</span> <span>thyroid hormones</span> <span>see <a title="target-block: amiodarone thyroid" href="PHP906-supraventricular-and-ventricular-arrhythmias.htm#PHP907">section 2.3.2</a></span>  </p></td><td></td></tr><tr><td><a href="bnf_int850-tolterodine.htm">Tolterodine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>amiodarone</span> <span>given with</span> <span>tolterodine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int217-trimethoprim.htm">Trimethoprim</a></td><td><p><span>possible increased risk of ventricular arrhythmias when </span> <span>amiodarone</span> <span>given with</span> <span>trimethoprim</span> <span>(as co-trimoxazole)—manufacturer of <span>amiodarone</span> advises avoid concomitant use of co-trimoxazole</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1227-vandetanib.htm">Vandetanib</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span> <span>amiodarone</span> <span>given with</span> <span>vandetanib</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int467-verapamil.htm">Verapamil</a></td><td class="cAI"><p><span>increased risk of bradycardia, AV block and myocardial depression when </span> <span>amiodarone</span> <span>given with</span> <span>verapamil</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int390-zuclopenthixol.htm">Zuclopenthixol</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>amiodarone</span> <span>given with</span> <span>zuclopenthixol</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr></tbody></table><p><strong>Disopyramide</strong> belongs to <strong>Anti-arrhythmics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int551-acetazolamide.htm">Acetazolamide</a></td><td class="cAI"><p><span>increased cardiac toxicity with </span> <span>disopyramide</span> <span>if hypokalaemia occurs with</span> <span>acetazolamide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>disopyramide</span> <span>given with</span> <span>amiodarone</span> <span>—avoid concomitant use</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int809-amisulpride.htm">Amisulpride</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>disopyramide</span> <span>given with</span> <span>amisulpride</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int241-antidepressants-tricyclic.htm">Antidepressants, Tricyclic</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>disopyramide</span> <span>given with</span> <span>tricyclics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int342-antimuscarinics.htm">Antimuscarinics</a></td><td><p><span>increased risk of antimuscarinic side-effects when </span> <span>disopyramide</span> <span>given with</span> <span>antimuscarinics</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Many drugs have antimuscarinic effects; concomitant use of two or more such drugs can increase side-effects such as dry mouth, urine retention, and constipation; concomitant use can also lead to confusion in the elderly. Interactions do not generally apply to antimuscarinics used by inhalation</p></div></td></tr><tr><td><a href="bnf_int1168-arsenic-trioxide.htm">Arsenic Trioxide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>disopyramide</span> <span>given with</span> <span>arsenic trioxide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int937-artemether-with-lumefantrine.htm">Artemether with Lumefantrine</a></td><td class="cAI"><p><span>avoidance of </span> <span>disopyramide</span> <span>advised by manufacturer of</span> <span>artemether/lumefantrine</span> <span>(risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1009-atomoxetine.htm">Atomoxetine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>disopyramide</span> <span>given with</span> <span>atomoxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int167-azithromycin.htm">Azithromycin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>disopyramide</span> <span>possibly increased by</span> <span>azithromycin</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>disopyramide</span> <span>possibly increased by</span> <span>clarithromycin</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int539-diuretics-loop.htm">Diuretics, Loop</a></td><td class="cAI"><p><span>increased cardiac toxicity with </span> <span>disopyramide</span> <span>if hypokalaemia occurs with</span> <span>loop diuretics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int525-diuretics-thiazide-and-related.htm">Diuretics, Thiazide and related</a></td><td class="cAI"><p><span>increased cardiac toxicity with </span> <span>disopyramide</span> <span>if hypokalaemia occurs with</span> <span>thiazides and related diuretics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1176-dronedarone.htm">Dronedarone</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>disopyramide</span> <span>given with</span> <span>dronedarone</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1152-droperidol.htm">Droperidol</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>disopyramide</span> <span>given with</span> <span>droperidol</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>disopyramide</span> <span>increased by</span> <span>erythromycin</span> <span>(increased risk of toxicity)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int1202-fingolimod.htm">Fingolimod</a></td><td class="cAI"><p><span>possible increased risk of bradycardia when </span> <span>disopyramide</span> <span>given with</span> <span>fingolimod</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int271-gliclazide.htm">Gliclazide</a></td><td><p><span></span> <span>disopyramide</span> <span>possibly enhances hypoglycaemic effect of</span> <span>gliclazide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int387-haloperidol.htm">Haloperidol</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span> <span>disopyramide</span> <span>given with</span> <span>haloperidol</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int265-insulin.htm">Insulin</a></td><td><p><span></span> <span>disopyramide</span> <span>possibly enhances hypoglycaemic effect of</span> <span>insulin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td class="cAI"><p><span>avoidance of </span> <span>disopyramide</span> <span>advised by manufacturer of</span> <span>itraconazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1050-ivabradine.htm">Ivabradine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>disopyramide</span> <span>given with</span> <span>ivabradine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>disopyramide</span> <span>given with</span> <span>ketoconazole</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int267-metformin.htm">Metformin</a></td><td><p><span></span> <span>disopyramide</span> <span>possibly enhances hypoglycaemic effect of</span> <span>metformin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int841-mizolastine.htm">Mizolastine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>disopyramide</span> <span>given with</span> <span>mizolastine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int973-moxifloxacin.htm">Moxifloxacin</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>disopyramide</span> <span>given with</span> <span>moxifloxacin</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int631-nitrates.htm">Nitrates</a></td><td><p><span></span> <span>disopyramide</span> <span>reduces effects of sublingual tablets of</span> <span>nitrates</span> <span>(failure to dissolve under tongue owing to dry mouth)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int808-pentamidine-isetionate.htm">Pentamidine Isetionate</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span> <span>disopyramide</span> <span>given with</span> <span>pentamidine isetionate</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span>metabolism of </span> <span>disopyramide</span> <span>accelerated by</span> <span>phenobarbital</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int373-phenothiazines.htm">Phenothiazines</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>disopyramide</span> <span>given with</span> <span>phenothiazines</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>plasma concentration of </span> <span>disopyramide</span> <span>reduced by</span> <span>phenytoin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int369-pimozide.htm">Pimozide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>disopyramide</span> <span>given with</span> <span>pimozide</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1147-ranolazine.htm">Ranolazine</a></td><td class="cAI"><p><span>avoidance of </span> <span>disopyramide</span> <span>advised by manufacturer of</span> <span>ranolazine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int199-rifamycins.htm">Rifamycins</a></td><td class="cAI"><p><span>metabolism of </span> <span>disopyramide</span> <span>accelerated by</span> <span>rifamycins</span> <span>(reduced plasma concentration)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to rifaximin</p></div></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>disopyramide</span> <span>possibly increased by</span> <span>ritonavir</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>disopyramide</span> <span>given with</span> <span>saquinavir</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int858-sildenafil.htm">Sildenafil</a></td><td><p><span>manufacturer of </span> <span>disopyramide</span> <span>advises avoid concomitant use with</span> <span>sildenafil</span> <span>(risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int455-sotalol.htm">Sotalol</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>disopyramide</span> <span>given with</span> <span>sotalol</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int371-sulpiride.htm">Sulpiride</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>disopyramide</span> <span>given with</span> <span>sulpiride</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int945-tadalafil.htm">Tadalafil</a></td><td><p><span>manufacturer of </span> <span>disopyramide</span> <span>advises avoid concomitant use with</span> <span>tadalafil</span> <span>(risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td class="cAI"><p><span>avoidance of </span> <span>disopyramide</span> <span>advised by manufacturer of</span> <span>telaprevir</span> <span>(risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int850-tolterodine.htm">Tolterodine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>disopyramide</span> <span>given with</span> <span>tolterodine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1227-vandetanib.htm">Vandetanib</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span> <span>disopyramide</span> <span>given with</span> <span>vandetanib</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int967-vardenafil.htm">Vardenafil</a></td><td><p><span>manufacturer of </span> <span>disopyramide</span> <span>advises avoid concomitant use with</span> <span>vardenafil</span> <span>(risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int467-verapamil.htm">Verapamil</a></td><td class="cAI"><p><span>increased risk of myocardial depression and asystole when </span> <span>disopyramide</span> <span>given with</span> <span>verapamil</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int222-warfarin.htm">Warfarin</a></td><td><p><span></span> <span>disopyramide</span> <span>may enhance or reduce anticoagulant effect of</span> <span>warfarin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int390-zuclopenthixol.htm">Zuclopenthixol</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>disopyramide</span> <span>given with</span> <span>zuclopenthixol</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr></tbody></table><p><strong>Flecainide</strong> belongs to <strong>Anti-arrhythmics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int551-acetazolamide.htm">Acetazolamide</a></td><td class="cAI"><p><span>increased cardiac toxicity with </span> <span>flecainide</span> <span>if hypokalaemia occurs with</span> <span>acetazolamide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>flecainide</span> <span>increased by</span> <span>amiodarone</span> <span>(halve dose of <span>flecainide</span>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int241-antidepressants-tricyclic.htm">Antidepressants, Tricyclic</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>flecainide</span> <span>given with</span> <span>tricyclics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int937-artemether-with-lumefantrine.htm">Artemether with Lumefantrine</a></td><td class="cAI"><p><span>avoidance of </span> <span>flecainide</span> <span>advised by manufacturer of</span> <span>artemether/lumefantrine</span> <span>(risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int440-beta-blockers.htm">Beta-blockers</a></td><td class="cAI"><p><span>increased risk of myocardial depression and bradycardia when </span> <span>flecainide</span> <span>given with</span> <span>beta-blockers</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</p></div></td></tr><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>metabolism of </span> <span>flecainide</span> <span>inhibited by</span> <span>cimetidine</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int364-clozapine.htm">Clozapine</a></td><td class="cAI"><p><span>increased risk of arrhythmias when </span> <span>flecainide</span> <span>given with</span> <span>clozapine</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div></td></tr><tr><td><a href="bnf_int539-diuretics-loop.htm">Diuretics, Loop</a></td><td class="cAI"><p><span>increased cardiac toxicity with </span> <span>flecainide</span> <span>if hypokalaemia occurs with</span> <span>loop diuretics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int525-diuretics-thiazide-and-related.htm">Diuretics, Thiazide and related</a></td><td class="cAI"><p><span>increased cardiac toxicity with </span> <span>flecainide</span> <span>if hypokalaemia occurs with</span> <span>thiazides and related diuretics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int234-fluoxetine.htm">Fluoxetine</a></td><td><p><span>plasma concentration of </span> <span>flecainide</span> <span>increased by</span> <span>fluoxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1019-fosamprenavir.htm">Fosamprenavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>flecainide</span> <span>possibly increased by</span> <span>fosamprenavir</span> <span>(increased risk of ventricular arrhythmias—avoid concomitant use)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Fosamprenavir is a prodrug of amprenavir</p></div></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>flecainide</span> <span>possibly increased by</span> <span>indinavir</span> <span>(increased risk of ventricular arrhythmias—avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int922-lopinavir.htm">Lopinavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>flecainide</span> <span>possibly increased by</span> <span>lopinavir</span> <span>(increased risk of ventricular arrhythmias—avoid concomitant use)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> In combination with ritonavir as Kaletra® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</p></div></td></tr><tr><td><a href="bnf_int841-mizolastine.htm">Mizolastine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>flecainide</span> <span>given with</span> <span>mizolastine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int341-quinine.htm">Quinine</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>flecainide</span> <span>increased by</span> <span>quinine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>flecainide</span> <span>possibly increased by</span> <span>ritonavir</span> <span>(increased risk of ventricular arrhythmias—avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>flecainide</span> <span>given with</span> <span>saquinavir</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td class="cAI"><p><span>caution with </span> <span>flecainide</span> <span>advised by manufacturer of</span> <span>telaprevir</span> <span>(risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int850-tolterodine.htm">Tolterodine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>flecainide</span> <span>given with</span> <span>tolterodine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int467-verapamil.htm">Verapamil</a></td><td class="cAI"><p><span>increased risk of myocardial depression and asystole when </span> <span>flecainide</span> <span>given with</span> <span>verapamil</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Lidocaine</strong> belongs to <strong>Anti-arrhythmics</strong> and has the following interaction information:</p><div class="cG"><p><strong>Note:</strong> Interactions less likely when lidocaine used topically</p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int551-acetazolamide.htm">Acetazolamide</a></td><td class="cAI"><p><span>action of </span> <span>lidocaine</span> <span>antagonised by hypokalaemia caused by</span> <span>acetazolamide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>lidocaine</span> <span>possibly increased by</span> <span>atazanavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>lidocaine</span> <span>increased by</span> <span>cimetidine</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1091-darunavir.htm">Darunavir</a></td><td><p><span>plasma concentration of </span> <span>lidocaine</span> <span>possibly increased by</span> <span>darunavir</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int539-diuretics-loop.htm">Diuretics, Loop</a></td><td class="cAI"><p><span>action of </span> <span>lidocaine</span> <span>antagonised by hypokalaemia caused by</span> <span>loop diuretics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int525-diuretics-thiazide-and-related.htm">Diuretics, Thiazide and related</a></td><td class="cAI"><p><span>action of </span> <span>lidocaine</span> <span>antagonised by hypokalaemia caused by</span> <span>thiazides and related diuretics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1019-fosamprenavir.htm">Fosamprenavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>lidocaine</span> <span>possibly increased by</span> <span>fosamprenavir</span> <span>—avoid concomitant use</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Fosamprenavir is a prodrug of amprenavir</p></div></td></tr><tr><td><a href="bnf_int922-lopinavir.htm">Lopinavir</a></td><td><p><span>plasma concentration of </span> <span>lidocaine</span> <span>possibly increased by</span> <span>lopinavir</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> In combination with ritonavir as Kaletra® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</p></div></td></tr><tr><td><a href="bnf_int793-propranolol.htm">Propranolol</a></td><td class="cAI"><p><span>increased risk of </span> <span>lidocaine</span> <span>toxicity when given with</span> <span>propranolol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>lidocaine</span> <span>given with</span> <span>saquinavir</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int628-suxamethonium.htm">Suxamethonium</a></td><td><p><span>neuromuscular blockade enhanced and prolonged when </span> <span>lidocaine</span> <span>given with</span> <span>suxamethonium</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td><p><span>caution with intravenous</span> <span>lidocaine</span> <span>advised by manufacturer of</span> <span>telaprevir</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Propafenone</strong> belongs to <strong>Anti-arrhythmics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int241-antidepressants-tricyclic.htm">Antidepressants, Tricyclic</a></td><td class="cAI"><p><span>increased risk of arrhythmias when </span> <span>propafenone</span> <span>given with</span> <span>tricyclics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td><p><span></span> <span>propafenone</span> <span>possibly increases plasma concentration of</span> <span>ciclosporin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>propafenone</span> <span>increased by</span> <span>cimetidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>propafenone</span> <span>enhances anticoagulant effect of</span> <span>coumarins</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td class="cAI"><p><span></span> <span>propafenone</span> <span>increases plasma concentration of</span> <span>digoxin</span> <span>(halve dose of <span>digoxin</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1019-fosamprenavir.htm">Fosamprenavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>propafenone</span> <span>possibly increased by</span> <span>fosamprenavir</span> <span>(increased risk of ventricular arrhythmias—avoid concomitant use)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Fosamprenavir is a prodrug of amprenavir</p></div></td></tr><tr><td><a href="bnf_int451-metoprolol.htm">Metoprolol</a></td><td><p><span></span> <span>propafenone</span> <span>increases plasma concentration of</span> <span>metoprolol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int841-mizolastine.htm">Mizolastine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>propafenone</span> <span>given with</span> <span>mizolastine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int647-neostigmine.htm">Neostigmine</a></td><td><p><span></span> <span>propafenone</span> <span>possibly antagonises effects of</span> <span>neostigmine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int236-paroxetine.htm">Paroxetine</a></td><td><p><span>metabolism of </span> <span>propafenone</span> <span>possibly inhibited by</span> <span>paroxetine</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int793-propranolol.htm">Propranolol</a></td><td><p><span></span> <span>propafenone</span> <span>increases plasma concentration of</span> <span>propranolol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int648-pyridostigmine.htm">Pyridostigmine</a></td><td><p><span></span> <span>propafenone</span> <span>possibly antagonises effects of</span> <span>pyridostigmine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>metabolism of </span> <span>propafenone</span> <span>accelerated by</span> <span>rifampicin</span> <span>(reduced effect)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>propafenone</span> <span>increased by</span> <span>ritonavir</span> <span>(increased risk of ventricular arrhythmias—avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>propafenone</span> <span>given with</span> <span>saquinavir</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td class="cAI"><p><span>caution with </span> <span>propafenone</span> <span>advised by manufacturer of</span> <span>telaprevir</span> <span>(risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int734-theophylline.htm">Theophylline</a></td><td><p><span></span> <span>propafenone</span> <span>increases plasma concentration of</span> <span>theophylline</span> <span></span>  </p></td><td></td></tr></tbody></table></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="bnf_int1176-dronedarone.htm" title="Dronedarone">Dronedarone</a></li><li><a href="bnf_int117-adenosine.htm" title="Adenosine">Adenosine</a></li><li><a href="bnf_int118-amiodarone.htm" title="Amiodarone">Amiodarone</a></li><li><a href="bnf_int119-disopyramide.htm" title="Disopyramide">Disopyramide</a></li><li><a href="bnf_int120-flecainide.htm" title="Flecainide">Flecainide</a></li><li><a href="bnf_int55-lidocaine.htm" title="Lidocaine">Lidocaine</a></li><li><a href="bnf_int125-propafenone.htm" title="Propafenone">Propafenone</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="bnf_int115-sodium-bicarbonate.htm">Previous: Sodium Bicarbonate</a> | <a class="top" href="bnf_int116-anti-arrhythmics.htm#">Top</a> | <a accesskey="]" href="bnf_int1176-dronedarone.htm">Next: Dronedarone</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>